Dr. Holman is Professor of Chemistry and Biochemistry at the University of California, Santa Cruz and a key opinion leader in the field of lipoxygenase biochemistry. He has investigated the biochemistry of lipoxygenases and their mechanism of inhibition for the past 25 years. His work led to the issuance of 11 patents focused on lipoxygenase inhibitors, with 4 focusing on the inhibition of human 12-lipoxygenase. Importantly, he is co-inventor of Veralox’s clinical product candidate. Dr. Holman received his PhD from University of Minnesota, Minneapolis and completed post-doctoral training at Harvard University and University of California, San Francisco.